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Prophylactic acyclovir has been shown to decrease the risk of
varicella zoster virus (VZV) reactivation following hemato-
poietic stem transplantation (HSCT). In order to improve
compliance and to minimize potential toxicity, we investi-
gated the role of a single daily ultra low-dose of acyclovir in
preventing the occurrence of herpes zoster (HZ) following
HSCT. Between June 2008 till date, all HSCT patients in this
center are being randomized after informed consent, to
either receive low-dose acyclovir (LD Group) at 800mg twice
daily (20mg/kg twice daily if <40kg or ultra low-dose
acyclovir (uLD Group) at 200mg once daily (5mg/kg/day if
<40kg) for one year following HSCT. The primary endpoint of
this study is the occurrence of HZ at one year. For this interim
per-protocol analysis, a total of 80 consecutive patients with
a minimum of 6 months of follow up following cessation of
therapy were eligible for analysis. There were 40 patients in
each group. Both groups were comparable for age, median 11
yrs (0.3-53) in the LD group vs 13 yrs (0.5-43) in the uLD
group, underlying disease, type of transplant, graft versus
host disease and median time of randomization (33.4 vs 38
days post HSCT). None of the patients in the uLD group
developed HZ while on prophylaxis. One patient in the LD
group developed HZ (2.5%). This patient had a past history of
recurrent herpes zoster in the same dermatomal distribution
prior to HSCT while on therapy for acute leukemia. Five
patients developed HZ within 5 months after discontinuing
acyclovir (LD group ¼ 1, uLD group ¼ 4, P ¼ .358). Amongst
these patients the median time to develop HZ after stopping
prophylaxis was 31 days (9-142 days). This prospective
randomized study shows that a single daily ultra low-dose of
acyclovir given for one year following HSCT is sufﬁcient to
prevent HZ during a time when the patient is most vulner-
able to the consequences of VZV reactivation. Prolongation of
prophylaxis beyond a year may be necessary for patients
who continue to be severely immunosuppressed.301
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Background: We have previously demonstrated the safety/
efﬁcacy of prophylactic liposomal amphotericin B (L-AMB) in
preventing IFI for 100 days in pediatric allogenic stem cell
transplant (AlloSCT) recipients (Roman/Cairo et al PBC,
2008). Prophylaxis with L-AMB 3 mg/kg/day (Day 0 to +44)
and micafungin (Day +45 to +100) has been shown by our
group to be both safe and effective in preventing IFI (Small/
Cairo et al ASBMT, 2011).
Methods: Pediatric AlloSCT recipients received low dose L-
AMB at 1.5 mg/kg IV daily (Day 0 to +44), followed by
micafungin 1.5 mg/kg (max 50 mg) (Day +45 to +100). Allpatients received Tacrolimus and MMF for acute GVHD
prophylaxis as we previously described Bhatia / Cairo, BBMT,
2010. Plasma galactomannan and beta-glucan assays were
monitored BIW. Treatment success was deﬁned as preven-
tion of IFI by day 100.
Results: 23 patients (8 ALL, 2 AML, 3 TNHL, 1 HL, 1 DLBCL, 2
SAA, 1 FA, 1 SCD, 2 CGD, 1 SCID, 1 HLH) Median age: 11.7 yrs
(1mo-23.5 yr) Sex: 3F, 20M Conditioning: 12 myeloablative,
11 reduced toxicity; 7 CB donors (6 -unrelated, 1-related), 2
related PBSC, 6 RBM , 7 URBM, and 1 RBM+CB. Median time
to myeloid and platelet engraftment was 17 and 32.5 days,
respectively. Chimerism ¼ 98-100% day +100. Absolute CD4
count day +100 was (29-439 cells/mL). Probability of Grade II-
IV aGVHD was 17% and cGVHD 4%. Probability of 1-yr OS was
87% (95% CI: 64.8-95.6). One patient, history of CGD, had IFI
Aspergillus spp on lung biopsy Day +49. Probability of IFI by
day 100 was 4% (95% CI 0-64.3). Grade 3-4 toxicities: renal
insufﬁciency with concomitant other nephrotoxins occurred
in 14 pts (60.8%), low K+ in 12 (52.1%), and low Mg++ in 5
(21.7%). L-AMB dosing was changed due to renal toxicity in
10 patients (decreased dose in 1, decreased frequency in 4,
changed to micafungin in 2, and held doses in 3). False
positive beta-glucan was observed in 8 and galactomannan
in 3 pts.
Conclusions: Low dose (1.5 mg/kg/day) L-AMB followed by
micafungin is as effective in preventing IFI as prior studied
higher doses (3 mg/kg/day). Future studies should focus on
reducing toxicity but maintaining efﬁcacy. Beta-glucan and
galactomannan assays may be associated with a high inci-
dence of false positive results in pediatric AlloSCT recipients
and should not be used alone in clinical decision making.302
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Background: In a large cancer center, the average in-patient
admission for Hematopoietic Stem Cell Transplant (HSCT)
patients ranges between three to ﬁve weeks based on the
type of transplant. HSCT patients may experience not only
physiological complications but also psychological,
emotional, and spiritual distress during hospitalization. A
number of HSCT patients are from out of state and may not
have adequate family support throughout the course of
hospitalization further aggravating patients’ level of distress.
Music Therapy is a complementary treatment that addresses
physical, emotional, cognitive, and social needs of individ-
uals. It was introduced to HSCT patients as a supportive
measure to assist in alleviating stressors experienced during
the hospital stay.
Purpose: A group of HSCT nurses wanted to evaluate the
patient perceived beneﬁts of music therapy on HSCT patients
during their hospitalization. A secondary aim of this project
was to explore the literature regarding music therapy, with
the potential for incorporating it as a standard of practice in
the care of HSCT patients.
Intervention: After conducting a review of literature on the
beneﬁts of music therapy on HSCT patients, HSCT nurses in
collaboration with Music Therapists promoted a regular
Abstracts / Biol Blood Marrow Transplant 19 (2013) S257eS278 S263program of music therapy during hospitalization. Music
therapy is available to HSCT patients as a weekly group
session, incorporated in an existing exercise class three times
a week, or on an individual consult basis.
Evaluation: At the end of each week, participants in music
therapy are asked to complete a short survey on their
perceptions of the effects of the therapy on a number of
factors, including stress, anxiety, sleep, comfort, pain and
others. Results will be used to reﬁne the program and
potentially lead to nursing research.
Discussion: Music therapy has been reported to reduce pain
and depression, promote rest and relaxation, and enhance
patient satisfaction. Given the complexities involved in
hematopoietic stem cell transplantation, interdisciplinary
collaboration between nurses and music therapists can
support the integration of music therapy to enhance patient
care outcomes and promote patient satisfaction.Figure 1.303
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Voriconazole has been increasingly used in the treatment of
invasive aspergillosis and for antifungal prophylaxis after
allogeneic BMT. The incidence of drug-induced skin reactions
is estimated to be 7%. There is a growing awareness of the
higher risk of acute and cumulative phototoxicity, and the
risk of chronic photo-damage and non-melanoma sun-
related skin cancers in immunocompromised patients.
Between August 2009 and June 2012, 40 of 43 consecutive
allo-BMT recipients (mean age 9.8 y; 83% Caucasian) received
voriconazole prophylaxis [7 mg/kg/dose BID (12 yrs age);
200 mg BID (>12 yrs); adjusted to target trough 1.0 mg/
mL]. Nine of forty (22.5%) patients, all Caucasian, developed
skin rashes in sun-exposed distributions during spring-
summer season. The average prior voriconazole exposure
was 6months (1.8e12.5mo). Dermatologic ﬁndings included
1) diffuse sunburn-like erythema over the face, outer aspects
of forearm, and hands 2) linear papulovesicular lesions 3)
severe bullous cheilitis (Figure 1) dermatoheliosis and 5)
lentigines. Voriconazole was continued in four, substituted
with ﬂuconazole in four and with posaconazole in one
patient. Patients were treated with sun avoidance, high-
potency sun-screens, and topical steroids with signiﬁcant
improvement in all cases.All (40) No Phototoxic
rash (31)
Phototoxic
rash (9)
Mean Vori- level (mg/ml) 1.3 1.2 1.5
Mean -N oxide (mg/ml) 3.5 3.2 4.8While trough voriconazole plasma concentrations do not
appear to be different, N-oxide metabolite concentrations
were higher in photosensitive patients.Signiﬁcant higherincidence of photosensitivity occurs in voriconazole-treated
children, especially Caucasians, during prolonged drug use
and intense sunshine. Voriconazole N-oxide may act as
a chromophore for phototoxicity, and its potential role in
individual susceptibility should be explored. Voriconazole
may be continued, although change to other azoles may be
necessary in some patients. Prolonged voriconazole use
requires close monitoring for chronic skin toxicities. Long-
term risks including the risk of skin cancer need to be
investigated.304
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Background: Although improvement of supportive cares
including antimicrobial prophylaxis has signiﬁcantly
ameliorated treatment outcomes in patients with hemato-
poietic stem cell transplantation (HSCT), bacterial blood-
stream infection (BSI) is still a major cause of morbidity and
mortality of HSCT. The purpose of this study is to evaluate
pre-transplant risk factors of BSI after HSCT and compare the
nature of BSIs between allogenic and autologous HSCT.
Methods: Adult patients (age  18 years) who received
either allogenic or autologous HSCT in a single institution
between November 2002 and June 2012, were analyzed.
Report of blood cultures from the start time of conditioning
therapy to hospital discharge, and clinical relevance of the
BSIs, were reviewed. Evaluated potential risk factors of BSI
were type of HSCT (allogenic vs. autologous), age, gender,
disease (AML vs. others), time from diagnosis to HSCT,
amount of infused CD34+ stem cell, HCT-CI score, and use of
antibiotics from conditioning for prophylactic or therapeutic
intent. Blood level of C-reactive protein (CRP), albumin, and
ferritin within 14 days from HSCT were also included in the
analysis. Among patients with allogenic HSCT, modiﬁed
EBMT score, concomitant acute GVHD, type of donor and
intensity of conditioning were additionally evaluated.
